Evaluation of Membrane Phospholipid and Energy Metabolism in Subjects at High Risk of Psychotic Transition
- Conditions
- Patients With Ultra High Risk of Psychotic Transition
- Interventions
- Diagnostic Test: Cerebral MRI with Phosphorus 31 Magnetic Resonance Spectroscopy
- Registration Number
- NCT05865652
- Lead Sponsor
- Centre Hospitalier Henri Laborit
- Brief Summary
The management of schizophrenia is a major public health issue, due to its particularly disabling psychotic symptoms and their onset at an early age, typically in adolescents or young adults.
The physiopathological hypothesis of an anomaly relating to the renewal of cell membranes and energy metabolism in schizophrenia was proposed as early as the 1930s. This is based on anomalies at certain times in the development of the balance between phosphomonesters, precursors of membrane phospholipids, and phosphodiesters, catabolites of membrane phospholipids. Alterations of these different balances sign neurodevelopmental disorders, and can be objectified by specific techniques such as phosphorus-31 magnetic resonance spectroscopy (SMR-31P). This is used in particular to characterize the energy metabolism of the brain and allows in vivo quantification of phosphorus metabolites.
The application of SMR-31P techniques to assess the metabolism of membrane phospholipids and cellular energy metabolism in subjects at high risk of psychotic transition could make it possible to objectify a difference between subjects subsequently suffering from a psychotic transition compared to those who do not suffer from it. Alterations in the metabolism of membrane phospholipids could thus represent a biomarker of psychotic transition. Secondarily, this approach would make it possible to provide elements as to the validity as a diagnosis of this category, which is very heterogeneous in its future.
Among the Ultra High Risk (UHR) group, subjects with a psychotic transition (UHR-T) are compared to subjects without this transition (UHR-NT) during the two years of follow-up.
The UHR group is compared to the control group.
At T0, UHR patients and healthy volunteers will perform brain MRI with Phosphorus 31 magnetic resonance spectroscopy.
UHR patients will then be reviewed:
* at T+1 year for a clinical assessment medical interview to assess the patient's functioning and the appearance of symptoms;
* at T+2 years for the realization of a follow-up interview with passing of the scales CAARMS (Comprehensive Assessment of At Risk Mental State) and SOFAS (scale of evaluation of the social and professional functioning) in order to determine if the subject belongs to the UHR-T or UHR-NT group.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 22
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Patient group Cerebral MRI with Phosphorus 31 Magnetic Resonance Spectroscopy Participants of this group are subjects with ultra high risk of psychotic transition. At inclusion visit, subjects will have a psychiatric evaluation and a cerebral MRI examination with phosphorus 31 Magnetic Resonance Spectroscopy in order to investigate membrane phospholipid metabolism and cellular energy metabolism. One and two years after the inclusion visit, subjects will have a psychiatric evaluation in order to objectivize if a psychotic transition has occured. Control group Cerebral MRI with Phosphorus 31 Magnetic Resonance Spectroscopy Participants of this group are healthy volunteers. Subjects will have one single visit with a psychiatric evaluation and a cerebral MRI examination with phosphorus 31 Magnetic Resonance Spectroscopy in order to investigate membrane phospholipid metabolism and cellular energy metabolism.
- Primary Outcome Measures
Name Time Method Difference of cellular Alpha ATP between UHR-T and UHR-NT patients. 2 years Levels measurements of Alpha ATP.
Difference of membrane phosphodiester alterations between UHR-T and UHR-NT patients. 2 years Levels measurements of phosphodiester.
Difference of intracellular pH between UHR-T and UHR-NT patients. 2 years Levels measurements of intracellular pH.
Difference of cellular inorganic phosphate between UHR-T and UHR-NT patients. 2 years Levels measurements of inorganic phosphate.
Difference of cellular phosphocreatine between UHR-T and UHR-NT patients. 2 years Levels measurements of phosphocreatine.
Difference of cellular Gamma ATP between UHR-T and UHR-NT patients. 2 years Levels measurements of Gamma ATP.
Difference of cellular beta ATP between UHR-T and UHR-NT patients. 2 years Levels measurements of beta ATP.
Difference of membrane phosphomonoester alterations between UHR-T and UHR-NT patients. 2 years Levels measurements of phosphomonoester.
- Secondary Outcome Measures
Name Time Method Difference of cellular intracellular pH between UHR subjects and control subjects. 2 years Levels measurements of intracellular pH.
Difference of cellular Gamma ATP between UHR subjects and control subjects. 2 years Levels measurements of Gamma ATP.
Difference of cellular Alpha ATP between UHR subjects and control subjects. 2 years Levels measurements of Alpha ATP.
Difference of membrane phosphomonoester alterations between UHR subjects and control subjects. 2 years Levels measurements of phosphomonoester.
Difference of cellular inorganic phosphate between UHR subjects and control subjects. 2 years Levels measurements of inorganic phosphate.
Difference of cellular beta ATP between UHR subjects and control subjects. 2 years Levels measurements of beta ATP.
Difference of cellular phosphocreatine between UHR subjects and control subjects. 2 years Levels measurements of phosphocreatine.
Difference of membrane phosphodiester alterations between UHR subjects and control subjects. 2 years Levels measurements of phosphodiester.
Trial Locations
- Locations (1)
Centre Hospitalier Henri Laborit
🇫🇷Poitiers, France